KRAS and neoplasm: Previous studies in patients with early-stage CRC and CRLM showed worse outcomes for patients with a KRAS G12V,49-53 G12C,50-53 or G12S49 tumor mutation compared with other frequently occurring G12 variants, like G12A and G12D.